NASDAQ:TWST

Twist Bioscience (TWST) Stock Forecast, Price & News

$16.16

+1.01 (+6.67%)

(As of 02:35 PM ET)

Compare

Today's Range: $14.75
▼
$16.27
50-Day Range: $11.49
▼
$16.28
52-Week Range: $11.46
▼
$58.76

Volume: 580,013 shs
Average Volume: 1.32 million shs
Market Capitalization: $923.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.17

Twist Bioscience MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 63.2% Upside
$26.17 Price Target
Short Interest: Bearish
24.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.42
Upright™ Environmental Score
News Sentiment: 0.74
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$132,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.96) to ($3.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

821st out of 1,980 stocks

Biological Products, Except Diagnostic Industry

111th out of 330 stocks

3.3

Analyst's Opinion

Consensus Rating
Twist Bioscience has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.17, Twist Bioscience has a forecasted upside of 63.2% from its current price of $16.03.
Amount of Analyst Coverage
Twist Bioscience has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
24.20% of the outstanding shares of Twist Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Twist Bioscience has a short interest ratio ("days to cover") of 9.9.
Change versus previous month
Short interest in Twist Bioscience has recently increased by 11.80%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Twist Bioscience does not currently pay a dividend.
Dividend Growth
Twist Bioscience does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Twist Bioscience has received a 65.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Deoxyribonucleic acid (DNA)" and "Monoclonal antibodies for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Twist Bioscience is -1.42.

3.2

News and Social Media Coverage

News Sentiment
Twist Bioscience has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Twist Bioscience this week, compared to 3 articles on an average week.
Search Interest
37 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 106% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Twist Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $132,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
11.80% of the stock of Twist Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Twist Bioscience are expected to grow in the coming year, from ($3.96) to ($3.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Twist Bioscience is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Twist Bioscience is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Twist Bioscience has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

June 1, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Stock Price Up 6.2%

May 31, 2023 | finanznachrichten.de

Twist Bioscience Corporation: Twist Bioscience to Present at ITF World 2023

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 26, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Stock Price Down 8.6%

May 24, 2023 | seekingalpha.com

Twist Bioscience: Progress On Margins Could Put A Floor Under The Stock

May 24, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Trading Up 5.1%

May 19, 2023 | seekingalpha.com

Reconsidering Twist Biosciences

May 14, 2023 | americanbankingnews.com

Dennis Cho Purchases 10,000 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 14, 2023 | americanbankingnews.com

Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

May 10, 2023 | americanbankingnews.com

Robert W. Baird Trims Twist Bioscience (NASDAQ:TWST) Target Price to $18.00

May 8, 2023 | msn.com

Barclays Maintains Twist Bioscience (TWST) Overweight Recommendation

May 8, 2023 | markets.businessinsider.com

Analyst Ratings for Twist Bioscience

May 8, 2023 | americanbankingnews.com

Barclays Lowers Twist Bioscience (NASDAQ:TWST) Price Target to $20.00

May 7, 2023 | finance.yahoo.com

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Call Transcript

May 5, 2023 | bizjournals.com

Despite record quarterly revenue, Twist Bioscience to cut 25% of workforce

May 5, 2023 | msn.com

Recap: Twist Bioscience Q2 Earnings

May 5, 2023 | americanbankingnews.com

Reviewing Taysha Gene Therapies (NASDAQ:TSHA) and Twist Bioscience (NASDAQ:TWST)

May 4, 2023 | benzinga.com

Earnings Preview: Twist Bioscience

May 4, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month Low at $11.89

May 3, 2023 | americanbankingnews.com

Twist Bioscience (TWST) to Release Quarterly Earnings on Friday

April 25, 2023 | americanbankingnews.com

Twist Bioscience Co. to Post Q2 2023 Earnings of ($1.04) Per Share, SVB Leerink Forecasts (NASDAQ:TWST)

April 23, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Price Target Cut to $20.00 by Analysts at The Goldman Sachs Group

April 20, 2023 | finance.yahoo.com

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

April 19, 2023 | americanbankingnews.com

Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $33.83

April 18, 2023 | msn.com

NVIDIA To Rally Over 31%? Here Are 10 Other Analyst Forecasts For Tuesday

April 14, 2023 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Sets New 52-Week Low at $12.96

See More Headlines

TWST Price History

30 days | 90 days | 365 days | Advanced Chart

TWST Company Calendar

Last Earnings: 5/05/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/04/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TWST
CUSIP: N/A
CIK: 1581280
Web: www.twistbioscience.com
Phone: (800) 719-0671
Fax: N/A
Employees: 652
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $26.17
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +70.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-217,860,000.00
Net Margins: -93.32%
Pretax Margin: -92.92%
Return on Equity: -27.95%
Return on Assets: -23.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.79
Quick Ratio: 6.23

Sales & Book Value

Annual Sales: $203.57 million
Price / Sales: 4.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.32 per share
Price / Book: 1.25

Miscellaneous

Outstanding Shares: 57,150,000
Free Float: 50,404,000
Market Cap: $878.97 million
Optionable: Not Optionable
Beta: 1.17

Key Executives

Emily Marine Leproust
Chairman & Chief Executive Officer

Patrick J. Finn
President & Chief Operating Officer

James M. Thorburn
Chief Financial Officer

Siyuan Chen
Chief Technology Officer

Nimisha Srivastava
Senior Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.
What is Twist Bioscience's stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $18.00 to $36.00. On average, they anticipate the company's stock price to reach $26.17 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.
How have TWST shares performed in 2023?: Twist Bioscience's stock was trading at $23.81 at the beginning of 2023. Since then, TWST shares have decreased by 35.4% and is now trading at $15.38.
View the best growth stocks for 2023 here.
When is Twist Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our TWST earnings forecast.
How were Twist Bioscience's earnings last quarter?: Twist Bioscience Co. (NASDAQ:TWST) announced its earnings results on Friday, May, 5th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $0.03. The business had revenue of $60.18 million for the quarter, compared to analysts' expectations of $56.61 million. Twist Bioscience had a negative net margin of 93.32% and a negative trailing twelve-month return on equity of 27.95%.
What ETFs hold Twist Bioscience's stock?: ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), ARK Innovation ETF (ARKK), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Hypatia Women CEO ETF (WCEO).
What guidance has Twist Bioscience issued on next quarter's earnings?: Twist Bioscience issued an update on its FY 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.00 million-$238.00 million, compared to the consensus revenue estimate of $264.18 million.
What is Emily Leproust's approval rating as Twist Bioscience's CEO?: 44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).
When did Twist Bioscience IPO?: (TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.
What is Twist Bioscience's stock symbol?: Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."
Who are Twist Bioscience's major shareholders?: Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.63%), BlackRock Inc. (10.93%), State Street Corp (9.23%), JPMorgan Chase & Co. (7.10%), Sumitomo Mitsui Trust Holdings Inc. (5.98%) and Nikko Asset Management Americas Inc. (5.98%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends.
How do I buy shares of Twist Bioscience?: Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Twist Bioscience's stock price today?: One share of TWST stock can currently be purchased for approximately $15.38.
How much money does Twist Bioscience make?: Twist Bioscience (NASDAQ:TWST) has a market capitalization of $878.97 million and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.77) on an earnings per share basis.
How many employees does Twist Bioscience have?: The company employs 652 workers across the globe.
How can I contact Twist Bioscience?: Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial